Pain
Therapeutics 2005: Market Dynamics and Outlook
provides detailed analysis and information concerning
the global market for pain therapeutics, R&D pipelines
and company involvement in this field. About one
and a half billion people suffer from moderate to
severe chronic pain worldwide and approximately
50 million Americans suffer with pain. The value
of the pharmaceutical market for pain relief reflects
this seeming worldwide epidemic of pain, with the
overall value reaching nearly $23 billion in 2004.
In
this new report, key pain management therapeutics
such as Cox-II inhibitors, opioids, triptans, anticonvulsants
and traditional NSAIDs are discussed in terms of
their past, present and future value and the role
they are playing in the effective management of
pain. The dynamics of this market have been altered
greatly over the past year. The troubles surrounding
the multi-billion dollar Cox-II class has created
a void in the marketplace.
Pain
Therapeutics 2005 explains just what the Cox-II
crisis means for the future of pain management and
what kinds of opportunities their failure may present
for other classes of pain management medications.
Pain
Therapeutics 2005 also analyzes the markets and
provides forecasts for:
This
249-page report also includes the following features:
-
93
tables/graphs which provide the reader with valuable
illustrated insight into trends and issues affecting
this growing market.
-
Thorough
financial breakdown of the leading products and
companies making an impact on the pain market
Identification and discussion of trends and issues
that are pushing the market into the future.
-
Profiles of key companies involved in the development
and marketing of pain therapeutics Forecasts of
key products/classes
|
